Avid Bioservices Inc (CDMO)

[RRdog]

Biopharm,

The following may help. My main point is you can not go straight from disease market size to valuation for PPHM. There is a "time" discounting and "risk" discounting before you "may" become SOC.

Description:


Globally, the Non-Small-Cell Lung Cancer (NSCLC) drug market will increase from USD 4.3 billion in 2009 to USD 6.9 billion in 2019 and the market is growing with a CAGR of 4.84% during 2009 to 2019. The major markets in these segments are the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The global top five global brands in NSCLC with the largest market share are Avastin, Tarceva, Alimta, Gemzar and Taxotere. For growth in the future there are drugs in the pipeline and in clinical trials at the phase 3 process development in the non small cell lung cancer market.



In the year 2012 many pipeline agents are going to be launched - such as Stimuvax and Aflibercept. The drugs that are in clinical trials phase 3 processes are vargatef (BIBF 1120), BIBW 2992, Crizotinib, Erbitux, ARQ 197, and Ramucirumab. In the NSCLC drug market, clinical trials have been discontinued due to the failure to meet the primary endpoint of overall survival in phase III non small cell lung cancer such as Nexavar, Sutent, AMG-706, Zactima, Figitumumab, ASA-404,

The high growth forecast is primarily attributed to the strong pipeline landscape, population growth and release of new first-in-class drugs with better safety and efficacy profiles. The NSCLC drugs market will grow due to smoking, secondary lifestyle, and other agents such as asbestos and radon, and air pollution.
- small-cell-

Best Regards,
RRdog